MA45469A - Acides nucléiques de bêta-caténine et leurs utilisations - Google Patents

Acides nucléiques de bêta-caténine et leurs utilisations

Info

Publication number
MA45469A
MA45469A MA045469A MA45469A MA45469A MA 45469 A MA45469 A MA 45469A MA 045469 A MA045469 A MA 045469A MA 45469 A MA45469 A MA 45469A MA 45469 A MA45469 A MA 45469A
Authority
MA
Morocco
Prior art keywords
beta
nucleic acids
catenin nucleic
catenin
acids
Prior art date
Application number
MA045469A
Other languages
English (en)
Inventor
Rob Burke
Hanhua Huang
Original Assignee
Avidity Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avidity Biosciences Llc filed Critical Avidity Biosciences Llc
Publication of MA45469A publication Critical patent/MA45469A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA045469A 2016-04-01 2017-03-31 Acides nucléiques de bêta-caténine et leurs utilisations MA45469A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662317123P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
MA45469A true MA45469A (fr) 2019-02-06

Family

ID=59965299

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045469A MA45469A (fr) 2016-04-01 2017-03-31 Acides nucléiques de bêta-caténine et leurs utilisations

Country Status (4)

Country Link
US (1) US10844385B2 (fr)
EP (1) EP3436582B1 (fr)
MA (1) MA45469A (fr)
WO (1) WO2017173297A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
WO2023122317A2 (fr) * 2021-12-23 2023-06-29 Aligos Therapeutics, Inc. MOLÉCULES D'ACIDE NUCLÉIQUE INTERFÉRENT COURT (SINA) POUR CIBLER LA β-CATÉNINE ET LEURS UTILISATIONS

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005519A1 (fr) 1985-03-15 1986-09-25 James Summerton Reactif et procede d'analyse de polynucleotides
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
WO1992007065A1 (fr) 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Ribozymes modifies
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5716824A (en) 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
DE69637256T2 (de) 1996-01-16 2008-06-19 Sirna Therapeutics, Inc., Boulder Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
WO1999054459A2 (fr) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
CA2328356A1 (fr) 1999-12-22 2001-06-22 Itty Atcravi Vehicules recreatifs
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
BRPI0117338B1 (pt) 2000-03-30 2016-06-21 Massachusetts Inst Technology método para produzir células animais nocauteadas in vitro e método para produzir uma célula nocauteada
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10133858A1 (de) 2001-07-12 2003-02-06 Aventis Pharma Gmbh Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US20040023220A1 (en) 2002-07-23 2004-02-05 Lawrence Greenfield Integrated method for PCR cleanup and oligonucleotide removal
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
ES2712695T3 (es) 2003-06-02 2019-05-14 Univ Massachusetts Métodos y composiciones para controlar la eficacia de la silenciación del ARN
AU2004252442B2 (en) 2003-06-02 2010-04-08 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of FNAi
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
WO2005014782A2 (fr) 2003-06-13 2005-02-17 Alnylam Europe Ag., Acide ribonucleique double brin presentant une efficacite accrue dans un organisme
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2568013C (fr) 2004-05-27 2015-11-24 Alnylam Pharmaceuticals, Inc. Acide ribonucleique double brin resistant aux nucleases
WO2008109369A2 (fr) * 2007-03-02 2008-09-12 Mdrna, Inc. Composés d'acide nucléique permettant d'inhiber l'expression de gène tnf et utilisations de ceux-ci
CN101849008A (zh) 2007-09-19 2010-09-29 应用生物系统有限公司 用于减少RNAi中的脱靶表型效应的siRNA的不依赖于序列的修饰形式和其稳定形式
US20110065774A1 (en) 2008-01-31 2011-03-17 Alnylam Pharmaceuticals Chemically modified oligonucleotides and uses thereof
EP2247729B1 (fr) 2008-02-11 2019-05-01 Phio Pharmaceuticals Corp. Polynucléotides d'arni modifiés et leurs utilisations
EP3208337A1 (fr) 2008-09-02 2017-08-23 Alnylam Pharmaceuticals, Inc. Compositions d'inhibition combiné d'expression du mutant egfr et il-6
EP2340309A2 (fr) 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Nanotransporteurs neutres
WO2010093788A2 (fr) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Molécules d'arn interférence substrats de dicer multiplexes ayant des séquences de jonction
JP2012526130A (ja) 2009-05-05 2012-10-25 アルテルムネ テクフノロジエス，エルエルシー 化学的にプログラム可能な免疫
DK2504435T3 (da) * 2009-11-26 2019-12-09 Quark Pharmaceuticals Inc Sirna-forbindelser omfattende terminale substitutioner
EP2591105B1 (fr) * 2010-07-06 2017-05-31 Dicerna Pharmaceuticals, Inc. Procédés et compositions pour l'inhibition spécifique de bêta-caténine par arn double brin
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
IL303831A (en) 2011-11-18 2023-08-01 Alnylam Pharmaceuticals Inc Adapted RNAI factors
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
EP3358013B1 (fr) * 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
CA2908096C (fr) 2013-03-27 2022-05-03 Isarna Therapeutics Gmbh Oligonucleotides tgf-beta modifies
US9861574B2 (en) 2013-04-09 2018-01-09 Duke University 2-fluoro-modified RNAs as immunostimulators
EP3610884B1 (fr) * 2013-11-06 2021-08-18 Merck Sharp & Dohme Corp. Conjugués contenant des peptides pour double distribution moléculaire d'oligonucléotides
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
WO2015200223A1 (fr) 2014-06-23 2015-12-30 Monsanto Technology Llc Compositions et méthodes de régulation de l'expression génétique par interférence par arn
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations

Also Published As

Publication number Publication date
WO2017173297A1 (fr) 2017-10-05
EP3436582B1 (fr) 2021-10-13
EP3436582A1 (fr) 2019-02-06
US20170314030A1 (en) 2017-11-02
US10844385B2 (en) 2020-11-24
EP3436582A4 (fr) 2020-02-12

Similar Documents

Publication Publication Date Title
FR24C1023I2 (fr) Anticorps thérapeutiques et leurs utilisations
IL272463A (en) Nucleic acid molecules and uses thereof
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3481430A4 (fr) Conjugués de type acide nucléique et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3349802A4 (fr) Dendrimères lipocationiques et leurs utilisations
EP3538261A4 (fr) Catalyseurs en pérovskite et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
EP3341007A4 (fr) Inhibiteurs de malt1 et leurs utilisations
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations
EP3347020A4 (fr) Acétamide thiénotriazoldiazépines et leurs utilisations
MA45470A (fr) Acides nucléiques kras et leurs utilisations
EP3370771A4 (fr) Conjugués anti-cd3-folate et leurs utilisations
MA46945A (fr) Exopolysaccharides et leurs utilisations
EP3377897A4 (fr) Biocapteurs de lactate et leurs utilisations
MA46562A (fr) Anticorps anti-chikv et leurs utilisations